Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Incyte Blood Cancer Drug Performs Well

By R&D Editors | December 21, 2010

WILMINGTON, Del. (AP) – Incyte Corp. said its primary drug candidate succeeded in a late-stage clinical trial that tested the drug as a treatment for myelofibrosis, a cancer of the blood.

The company said 42 percent of patients treated with INCB18424 experienced a significant reduction in swelling of the spleen, which is a common symptom of myelofibrosis. Among patients treated with a placebo, less than 1 percent had a similar reduction. Incyte said this study was the only late-stage trial it is being required to conduct to support approval in the U.S.

Incyte said 309 patients were enrolled in the study, and results were taken 24 weeks after treatment. The most common side effects of treatment with INCB18424 were anemia and thrombocytopenia, or a lack of blood platelets. It said the thrombocytopenia was reversible.

Shares of Incyte picked up 16 cents to close at $15.18 Monday before the test results were issued. The stock rose 67 cents, or 4.4 percent, to $15.85 in aftermarket trading.

The company said there are no approved treatments for myelofibrosis. INCB18424 has received orphan drug status in the U.S. and the European Union. Orphan drug status is given to drugs that could treat rare conditions, and it includes incentives such as extended market exclusivity following approval, assistance in clinical trial design, reduced fees, and tax credits.

Incyte is developing INCB18424 through a partnership with Novartis AG, which is conducting a second late-stage trial in Europe. The company said results from that study are due in early 2011. In addition to myelofibrosis, the drug is being tested as a treatment for the blood disorders polycythemia vera and essential thrombocythemia. It is also being studied against solid tumors and psoriasis.

Date: December 20, 2010
Source: Associated Press

Related Articles Read More >

2025 R&D layoffs tracker hits 132,075 as Amazon CEO signals AI will cut more jobs
Probiotics power a bioresorbable battery that can run from 4 to 100+ minutes
Health-related innovation in Morocco highlighted by resident inventor patenting activity
ARPA-H funds $29M Ginkgo-led project to reshore pharma supply chains using wheat germ tech
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE